Hemodialysis PatientsPhase 3NCT00491868
Clinical Study of R744 to Hemodialysis Patients
A Phase 3 study testing R744 and rHuEPO in people with Hemodialysis Patients, run by Chugai Pharmaceutical at 5 sites in Japan.
Trial summary
This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of intravenous injections of R744 in renal anemia patients on Hemodialysis patients. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Hemodialysis Patients
- What is being tested?
- R744 and rHuEPO
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 134 participants
- Where
- 5 sitesJapan
- Study dates
- Jun 2007to Aug 2008
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration
- Patients aged ≥ 20 years at the time of obtaining consent
- Patients who have been receiving a rHuEPO preparation at least once a week for at least 8 weeks before registration
- Within 4 weeks before registration, patients who have been receiving a rHuEPO preparation 750IU (3 times a week), 1,500IU (twice a week (1st and 2nd hemodialysis day of the week, or1st and 3rd hemodialysis day of the week)), 1,500IU (3 times a week), or 3,000IU (twice a week (1st and 2nd hemodialysis day of the week, or1st and 3rd hemodialysis day of the week)), and patients who have not change dosage and administration.
- Patients whose pre-dialysis Hb concentrations has been between ≥ 9.0 g/dL and ≤12.0 g/dL and mean value of pre-dialysis Hb concentrations has been between ≥ 9.5 g/dL and ≤11.5 g/dL determined at the beginning of each week within 8 weeks before registration
- Patients whose transferrin saturation has been ≥ 20 % or ferritin has been ≥ 100ng/mL at any time point within 8 weeks before registration
Who cannot join
- Patients with hardly controllable hypertension (patients whose diastolic blood pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12 weeks before registration)
- Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function classification)
- Female patients who are pregnant, lactating, possibly pregnant or not willing to take a contraceptive measure in the period from the day of starting the treatment with the study drug to 90 days after the day of the last dose of the study drug
- Patients with complication of myocardial infarction, pulmonary infarction or cerebral infarction (excluding asymptomatic cerebral infarction)
- Patients confirmed to have serious allergy or serious drug allergy (shock, anaphylactoid symptom)
- Patients hypersensitive to a rHuEPO preparation
Show all 14Show fewer
- Patients with malignant tumor (including hemic malignant tumor), severe infection, systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.), hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage
- Patients who have received an anabolic hormone preparation, testosterone enanthate, testosterone propionate, methyltestosterone or mepitiostane within 12 weeks before registration
- Patients who have received another investigational drug within 12 weeks before registration
- Patients who have received R744 before registration
- Patients whose AST(GOT) value ≥ 100 IU/L or ALT(GPT) value ≥ 100 IU/L before registration
- Patients who have received erythrocyte transfusion within 16 weeks before registration
- Patients for whom a surgical operation accompanied by marked bleeding is planned during the study period
- In addition, patients who are judged as ineligible to participate in this study by the investigator or subinvestigator
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Japan5 sites
Chubu region
Chūbu
Chugoku/Shikoku region
Chugoku/Shikoku
Kanto/Koshinetsu region
Kanto/Koshinetsu
Kinki/Hokuriku region
Kinki/Hokuriku
Kyusyu region
Kyusyu
About this study
Official title: Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase III, Double Blind Study in Comparison With Epoetin Beta).
This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of intravenous injections of R744 in renal anemia patients on Hemodialysis patients.
- Conditions
- Hemodialysis Patients
- Being tested
- R744, rHuEPO, R744 placebo, rHuEPO placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
R744Drug
Also called methoxy polyethylene glycol-epoetin beta
100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
R744Drug
Also called methoxy polyethylene glycol-epoetin beta
150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
rHuEPODrug
2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
rHuEPODrug
4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
R744 placeboDrug
0 μg/4week for 24 weeks
rHuEPO placeboDrug
0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: R744; Drug: rHuEPO placebo |
| 2 | Experimental | Not described Receives: Drug: R744; Drug: rHuEPO placebo |
| 3 | Active comparator | Not described Receives: Drug: rHuEPO; Drug: R744 placebo |
| 4 | Active comparator | Not described Receives: Drug: rHuEPO; Drug: R744 placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Variation of Hb concentration from baseline Hb concentration in evaluation period
Measured: week 17~24
Secondary outcomes (7)
Rate of patients who maintain Hb concentration in the range of baseline ± 1.0g/dL and maintain Hb concentration in the range of ≥ 9.0g/dL and ≤ 12.0g/dL in evaluation period
Measured: week 17~24
Rate of patients who maintain Hb concentration within ±1.0g/dL of reference Hb
Measured: week 17~24
Adverse events
Measured: throughout study
Laboratory measurements
Measured: throughout study
Vital signs, standard 12-lead ECG
Measured: throughout study
Anti-R744 antibody titer
Measured: throughout study
Anti-Epoetin beta antibody titer
Measured: throughout study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2007 (estimated)
- Study startJun 2007
- Primary completionMay 2008
- Study completionAug 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemodialysis PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 134 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chugai Pharmaceutical
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Takanori Baba, Study chair, Chugai Pharmaceutical,Clinical Research Department 2
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00491868
- Sponsor's protocol ID
- JH20876
- Status last verified
- Jan 2009
- First submitted
- 25 Jun 2007
- Last updated
- 2 Feb 2009
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase III, Double Blind Study in Comparison With Epoetin Beta).
- ClinicalTrials.gov ID
- NCT00491868
- Acronym / sponsor ID
- JH20876
- Conditions
- Hemodialysis Patients
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 134 participants (actual)
- Lead sponsor
- Chugai PharmaceuticalIndustry (pharma, biotech, devices)
- Study start
- Jun 2007
- Primary completion
- May 2008 (actual)
- Study completion
- Aug 2008 (actual)
- First posted
- 26 Jun 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of intravenous injections of R744 in renal anemia patients on Hemodialysis patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: R744, Drug: rHuEPO placebo |
| 2 | Experimental | Drug: R744, Drug: rHuEPO placebo |
| 3 | Active comparator | Drug: rHuEPO, Drug: R744 placebo |
| 4 | Active comparator | Drug: rHuEPO, Drug: R744 placebo |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration
- Patients aged ≥ 20 years at the time of obtaining consent
- Patients who have been receiving a rHuEPO preparation at least once a week for at least 8 weeks before registration
- Within 4 weeks before registration, patients who have been receiving a rHuEPO preparation 750IU (3 times a week), 1,500IU (twice a week (1st and 2nd hemodialysis day of the week, or1st and 3rd hemodialysis day of the week)), 1,500IU (3 times a week), or 3,000IU (twice a week (1st and 2nd hemodialysis day of the week, or1st and 3rd hemodialysis day of the week)), and patients who have not change dosage and administration.
- Patients whose pre-dialysis Hb concentrations has been between ≥ 9.0 g/dL and ≤12.0 g/dL and mean value of pre-dialysis Hb concentrations has been between ≥ 9.5 g/dL and ≤11.5 g/dL determined at the beginning of each week within 8 weeks before registration
Key exclusion criteria (14 listed)
- Patients with hardly controllable hypertension (patients whose diastolic blood pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12 weeks before registration)
- Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function classification)
- Female patients who are pregnant, lactating, possibly pregnant or not willing to take a contraceptive measure in the period from the day of starting the treatment with the study drug to 90 days after the day of the last dose of the study drug
- Patients with complication of myocardial infarction, pulmonary infarction or cerebral infarction (excluding asymptomatic cerebral infarction)
- Patients confirmed to have serious allergy or serious drug allergy (shock, anaphylactoid symptom)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| R744Also: methoxy polyethylene glycol-epoetin beta100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks | Drug | 1 |
| R744Also: methoxy polyethylene glycol-epoetin beta150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks | Drug | 2 |
| rHuEPO2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks | Drug | 3 |
| rHuEPO4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks | Drug | 4 |
| R744 placebo0 μg/4week for 24 weeks | Drug | 3, 4 |
| rHuEPO placebo0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks | Drug | 1, 2 |
Primary outcome
Variation of Hb concentration from baseline Hb concentration in evaluation period
Time frame: week 17~24
7 secondary outcomes
Rate of patients who maintain Hb concentration in the range of baseline ± 1.0g/dL and maintain Hb concentration in the range of ≥ 9.0g/dL and ≤ 12.0g/dL in evaluation period
Time frame: week 17~24
Rate of patients who maintain Hb concentration within ±1.0g/dL of reference Hb
Time frame: week 17~24
Adverse events
Time frame: throughout study
Laboratory measurements
Time frame: throughout study
Vital signs, standard 12-lead ECG
Time frame: throughout study
Anti-R744 antibody titer
Time frame: throughout study
Anti-Epoetin beta antibody titer
Time frame: throughout study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2009.
Related trials for Hemodialysis Patients
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Not yet recruitingPhase 1/2
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
End Stage Renal Disease, Fatigue
Active, not recruitingPhase 2
Management of Iron Deficiency Anemia in Hemodialysis Patients
Iron Deficiency Anemia (IDA), ESRD (End Stage Renal Disease)
Not yet recruitingObservational study
Malnutrition and Sarcopenia in Adults With Chronic Kidney Disease in Tunisia
Malnutrition, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Takanori Baba study chair
Chugai Pharmaceutical,Clinical Research Department 2
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing R744 and rHuEPO in people with Hemodialysis Patients, run by Chugai Pharmaceutical at 5 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Feb 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Variation of Hb concentration from baseline Hb concentration in evaluation period (time frame: week 17~24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2009.